Navigation Links
Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
Date:2/4/2010

RESEARCH TRIANGLE PARK, N.C., Feb. 4 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that Gwendolyn Powell Painter, M.D., M.P.H., has joined the company as Chief Medical Officer.  

Dr. Painter has more than 20 years of experience in the pharmaceutical industry, including work in clinical development, clinical safety and pharmacovigilance, and occupational and environmental medicine.  In her role as Chief Medical Officer, Dr. Painter will be responsible for clinical strategy and development of Chimerix's proprietary antiviral medicines addressing life-threatening diseases.  Dr. Painter has been working with Chimerix since 2002 in a consulting capacity, providing medical oversight and clinical consulting.  

"We are delighted to have Wendy join our leadership team.  Her extensive background in all phases of antiviral drug development has been and will be invaluable as we advance our pipeline through the clinical trials process," said Kenneth I. Moch, Chimerix's Chief Operating Officer.  "Wendy has been a vital force in the development of our broad-spectrum antiviral candidate CMX001."

Dr. Painter has an extensive background in drug development at a number of biotechnology and pharmaceutical companies.  Her experience includes having served as Medical Director at GlaxoSmithKline (GSK) where she had responsibility for worldwide antiviral clinical safety.  While there, she was involved in a number of antiviral Investigational New Drug (IND) applications and New Drug Application (NDA) submissions to the U.S. Food and Drug Administration.  Subsequently, she provided expert medical consulting to a range of biotechnology and pharmaceutical companies regarding drug development.  Dr. Painter earned an M.S. in Organic Chemistry at Emory University and an M.D. degree at the University of Miami School Of Medicine.  She later obtained a Master of Public Health degree in Epidemiology at the University of North Carolina at Chapel Hill and completed a fellowship in occupational medicine at Duke University where she maintains an academic appointment.

About Chimerix

Chimerix, Inc., is developing antiviral therapeutics to treat life-threatening diseases.  Led by a world-class antiviral drug development team, Chimerix is advancing programs to address cytomegalovirus (CMV), BK virus, smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza.  The company's lead compound, CMX001, is currently in Phase 1 and 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections among immunocompromised patients.  CMX001 is also being developed as a biodefense countermeasure in the event of a smallpox release.  Chimerix has received financing from leading venture capital firms, including Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Company and Frazier Healthcare Ventures, in addition to significant funding from the National Institute of Allergy and Infectious Diseases.  Additional information about Chimerix and its antiviral drug development programs may be found online at http://www.chimerix-inc.com.

SOURCE Chimerix, Inc.

RELATED LINKS
http://www.chimerix-inc.com

'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer
2. Merial to Screen Chimerix Chemical Library for Animal Health Drug Leads
3. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
4. Chimerix Joins International Network of Organizations to Cure Malaria
5. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
6. KGI Names Kerry Howell Vice President for Advancement
7. Vical Names Andrew de Guttadauro Vice President, Corporate Development
8. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
9. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
10. CryoLife Names Philip Theodore as Vice President, General Counsel
11. Genstar Names Michael Hurt to Its Strategic Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... In starting a program to hire ... grandfather, “Hire for attitude. Train for skill.” , In keeping with this philosophy, the ... as a salesman. Zamzow is hoping to replicate the practice throughout the company. , ...
(Date:2/24/2017)... ... February 24, 2017 , ... A study recently published ... an ambulatory surgery center (ASC) with satisfactory clinical and patient-reported outcomes, when compared ... , Jake Lubinski, president of AxioMed, commented on the recent publication, stating, ...
(Date:2/24/2017)... 2017  Aethlon Medical, Inc. (Nasdaq: AEMD ... Chairman and CEO, Jim Joyce . ... last Saturday, Bill Gates warned world leaders ... than nuclear weapons. Mr. Gates expressed his concern, which ... that scientific terrorists have access to the necessary tools ...
(Date:2/24/2017)... , ... February 24, 2017 , ... FireflySci, Inc is ... in late 2014, FireflySci had the goal of bringing their powerful cuvette ... to shape the path that FireflySci is going on as they add yet another ...
Breaking Biology Technology:
(Date:2/22/2017)... -- With the biometrics market to exceed $10 ... that innovative and agile startups must incorporate into ... changing competitive landscape: multifactor authentication (MFA), point-of-sale (PoS), ... "Companies can no longer afford to cut corners ... Pavlakis , Industry Analyst at ABI Research. "Pairing ...
(Date:2/16/2017)...  Genos, a community for personal genetic discovery ... Laboratory Accreditation from the College of American Pathologists ... that meet stringent requirements around quality, accuracy and ... "Genos is committed to maintaining the highest ... to be receiving CAP accreditation," said Jill ...
(Date:2/13/2017)... -- Former 9/11 Commission border counsel and Special Counsel ... of Identity Strategy Partners, LLP, today releases the ... Order: Protecting the Nation From Foreign Terrorist Entry Into ... President Trump,s ,Travel Ban, Executive Order gains more notoriety ... travel ban, it is important that our national discourse ...
Breaking Biology News(10 mins):